Zoetis Misses Q1 Earnings Expectations, Lowers 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 03 2024
0mins
Source: Fool
Zoetis Inc's stock fell 12.76% in pre-market trading, hitting a 52-week low of $96.99, following disappointing Q1 earnings results and a downward revision of its 2026 revenue guidance.
The company reported Q1 non-GAAP EPS of $1.53, missing expectations by $0.09, and revised its 2026 revenue guidance to a range of $9.68 billion to $9.96 billion, below the consensus of $9.89 billion. This reflects a cautious outlook amid increasing market competition and challenges in profitability, as the adjusted EPS guidance was lowered to $6.85 to $7.00, below market expectations of $7.03.
The market reaction indicates investor caution regarding Zoetis's future growth potential, despite a year-over-year revenue increase of 4.5% to $2.3 billion in Q1. The company's ability to maintain profitability is under scrutiny as it navigates a competitive landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 78.270
Low
130.00
Averages
154.20
High
200.00
Current: 78.270
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Rated as One of the Best Wide Moat Stocks by Wall Street Analysts
- Performance Adjustment: Citi has lowered Zoetis' price target from $145 to $112 while maintaining a 'Buy' rating, reflecting analysts' cautious outlook on the company's future performance, particularly after a disappointing Q1 2026 report.
- Revenue Growth Analysis: In Q1 2026, Zoetis reported revenue of $2.3 billion, marking a 3% year-over-year increase; however, U.S. revenue of $1.1 billion declined by 8%, indicating an 11% drop in companion animal product sales due to weaker market demand.
- Future Outlook: The company anticipates FY 2026 revenue between $9.680 billion and $9.960 billion, with adjusted net income expected between $2.870 billion and $2.950 billion, reflecting organic operational growth expectations of 2% to 6%, showcasing resilience amid market fluctuations.
- Market Competition Insight: Despite Zoetis' leading position in animal health, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, indicating potential challenges to Zoetis' investment appeal.
See More
Zoetis Faces Class Action Lawsuit Allegations
- Lawsuit Background: Zoetis Inc. is facing a class action lawsuit for securities transactions between January 14, 2025, and May 6, 2026, with allegations against its executives for violating the Securities Exchange Act of 1934, potentially leading to significant investor losses.
- Declining Market Performance: The second quarter 2025 financial results revealed weakening demand for Zoetis' companion animal products, causing a nearly 4% drop in stock price, indicating declining investor confidence in its key offerings.
- Increased Competitive Pressure: Following FDA safety warnings regarding Zoetis' Librela, veterinarian prescription growth has sharply weakened, while Simparica Trio is losing market share to lower-priced competitors, further impacting the company's performance.
- Pessimistic Financial Outlook: The first quarter 2026 financial results showed slowing overall revenue growth and poor companion animal sales performance, leading to a stock price decline of over 21%, highlighting the severe challenges Zoetis faces in a competitive market.
See More
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: From June 2025 to March 2026, AeroVironment is accused of failing to disclose imminent competition, misleading investors about its business prospects, which could negatively impact stock prices and investor confidence.
- Calix Lawsuit: Calix's first-quarter margins were significantly influenced by advanced memory component purchases, yet the company did not inform investors about dwindling supplies, leading to negative margin pressure that may adversely affect future financial performance.
- Zoetis Lawsuit: During the period from January 2025 to May 2026, Zoetis failed to disclose a significant decline in veterinarian prescription growth due to FDA safety warnings, potentially weakening investor confidence in its market position and affecting stock prices.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz to understand their rights in these class actions, indicating that the legal risks faced by these companies could influence shareholder investment decisions.
See More
Zoetis Faces Securities Class Action Lawsuit from Shareholders
- Lawsuit Background: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Investor Action: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by July 27, 2026, with the understanding that participation does not require lead plaintiff status to share in any recovery.
- Potential Losses: The lawsuit claims that due to significant misrepresentations regarding the company's operations, growth prospects, and financial stability, investors suffered substantial losses when the truth was revealed, indicating a severe impact on confidence in the company's future.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, underscoring its strong reputation and influence in the securities litigation field.
See More
Class Action Lawsuit Announced for Zoetis Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Zoetis Inc. (NYSE:ZTS) securities purchasers from January 14, 2025, to May 6, 2026, indicating potential investor losses due to misleading statements, which could adversely affect the company's reputation and stock price.
- Compensation Mechanism: Investors participating in the lawsuit will not incur any upfront costs through a contingency fee arrangement, aimed at reducing financial burdens on investors and encouraging more affected parties to join the litigation for compensation.
- Market Share Decline: The lawsuit highlights that Zoetis' products like Librela and Simparica Trio are losing market share due to FDA safety warnings and competitive pricing strategies, reflecting increased competitive pressure in the veterinary market that may impact future sales growth.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Class Action Filed Against Zoetis for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Zoetis Inc. aimed at recovering damages for investors who purchased securities between January 14, 2025, and May 6, 2026, reflecting significant investor dissatisfaction with the company's transparency.
- False Statements Allegations: The complaint alleges that Zoetis made materially false and misleading statements regarding the growth and market share of key products, particularly concerning veterinarian adoption of Librela and Simparica Trio, failing to disclose significant declines in market share.
- Competitive Pressure: Zoetis' Simparica Trio is losing substantial market share to lower-priced competitors with broader indications, indicating the company's vulnerability in a slowing overall market and raising concerns about its competitive positioning.
- Investor Action Recommendations: Affected investors are encouraged to apply to be lead plaintiffs by July 27, 2026, indicating that the legal challenges faced by the company could impact its future financial performance and market confidence.
See More
Zoetis Rated as One of the Best Wide Moat Stocks by Wall Street Analysts
- Performance Adjustment: Citi has lowered Zoetis' price target from $145 to $112 while maintaining a 'Buy' rating, reflecting analysts' cautious outlook on the company's future performance, particularly after a disappointing Q1 2026 report.
- Revenue Growth Analysis: In Q1 2026, Zoetis reported revenue of $2.3 billion, marking a 3% year-over-year increase; however, U.S. revenue of $1.1 billion declined by 8%, indicating an 11% drop in companion animal product sales due to weaker market demand.
- Future Outlook: The company anticipates FY 2026 revenue between $9.680 billion and $9.960 billion, with adjusted net income expected between $2.870 billion and $2.950 billion, reflecting organic operational growth expectations of 2% to 6%, showcasing resilience amid market fluctuations.
- Market Competition Insight: Despite Zoetis' leading position in animal health, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, indicating potential challenges to Zoetis' investment appeal.
See More
Zoetis Faces Class Action Lawsuit Allegations
- Lawsuit Background: Zoetis Inc. is facing a class action lawsuit for securities transactions between January 14, 2025, and May 6, 2026, with allegations against its executives for violating the Securities Exchange Act of 1934, potentially leading to significant investor losses.
- Declining Market Performance: The second quarter 2025 financial results revealed weakening demand for Zoetis' companion animal products, causing a nearly 4% drop in stock price, indicating declining investor confidence in its key offerings.
- Increased Competitive Pressure: Following FDA safety warnings regarding Zoetis' Librela, veterinarian prescription growth has sharply weakened, while Simparica Trio is losing market share to lower-priced competitors, further impacting the company's performance.
- Pessimistic Financial Outlook: The first quarter 2026 financial results showed slowing overall revenue growth and poor companion animal sales performance, leading to a stock price decline of over 21%, highlighting the severe challenges Zoetis faces in a competitive market.
See More
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: From June 2025 to March 2026, AeroVironment is accused of failing to disclose imminent competition, misleading investors about its business prospects, which could negatively impact stock prices and investor confidence.
- Calix Lawsuit: Calix's first-quarter margins were significantly influenced by advanced memory component purchases, yet the company did not inform investors about dwindling supplies, leading to negative margin pressure that may adversely affect future financial performance.
- Zoetis Lawsuit: During the period from January 2025 to May 2026, Zoetis failed to disclose a significant decline in veterinarian prescription growth due to FDA safety warnings, potentially weakening investor confidence in its market position and affecting stock prices.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz to understand their rights in these class actions, indicating that the legal risks faced by these companies could influence shareholder investment decisions.
See More
Zoetis Faces Securities Class Action Lawsuit from Shareholders
- Lawsuit Background: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Investor Action: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by July 27, 2026, with the understanding that participation does not require lead plaintiff status to share in any recovery.
- Potential Losses: The lawsuit claims that due to significant misrepresentations regarding the company's operations, growth prospects, and financial stability, investors suffered substantial losses when the truth was revealed, indicating a severe impact on confidence in the company's future.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, underscoring its strong reputation and influence in the securities litigation field.
See More
Class Action Lawsuit Announced for Zoetis Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Zoetis Inc. (NYSE:ZTS) securities purchasers from January 14, 2025, to May 6, 2026, indicating potential investor losses due to misleading statements, which could adversely affect the company's reputation and stock price.
- Compensation Mechanism: Investors participating in the lawsuit will not incur any upfront costs through a contingency fee arrangement, aimed at reducing financial burdens on investors and encouraging more affected parties to join the litigation for compensation.
- Market Share Decline: The lawsuit highlights that Zoetis' products like Librela and Simparica Trio are losing market share due to FDA safety warnings and competitive pricing strategies, reflecting increased competitive pressure in the veterinary market that may impact future sales growth.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Class Action Filed Against Zoetis for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Zoetis Inc. aimed at recovering damages for investors who purchased securities between January 14, 2025, and May 6, 2026, reflecting significant investor dissatisfaction with the company's transparency.
- False Statements Allegations: The complaint alleges that Zoetis made materially false and misleading statements regarding the growth and market share of key products, particularly concerning veterinarian adoption of Librela and Simparica Trio, failing to disclose significant declines in market share.
- Competitive Pressure: Zoetis' Simparica Trio is losing substantial market share to lower-priced competitors with broader indications, indicating the company's vulnerability in a slowing overall market and raising concerns about its competitive positioning.
- Investor Action Recommendations: Affected investors are encouraged to apply to be lead plaintiffs by July 27, 2026, indicating that the legal challenges faced by the company could impact its future financial performance and market confidence.
See More
